NICE green light for Roche’s Rozlytrek
The drug targets all solid tumours with the NTRK gene fusions
Read Moreby Selina McKee | Jun 25, 2020 | News | 0
The drug targets all solid tumours with the NTRK gene fusions
Read Moreby Selina McKee | May 27, 2020 | News | 0
Evidence from trials suggests that tumours with NTRK gene fusions shrink in response to larotrectinib
Read Moreby Selina McKee | May 30, 2018 | News | 0
Bayer/Loxo Oncology’s larotrectinib has been granted a priority review by the US Food and Drug Administration, which will consider its use to treat metastatic solid tumours carrying a certain genetic mutation.
Read Moreby Selina McKee | Jan 2, 2018 | News | 0
Roche has announced plans to buy US group Ignyta for $27 a share in an all-cash deal totaling around $1.7 billion, securing itself access to the latter’s experimental cancer medicines.
Read Moreby Selina McKee | Dec 18, 2017 | News | 0
Cambridge, UK-based Horizon Discovery has expanded its relationship with Roche Diagnostics with a new agreement to assist in the development of immunohistochemistry (IHC) assays.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
